JESSICA NAGRO

FY20 Appropriations for Psoriatic Disease Allocate $1 million in the Fiscal Year 2020 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.

In relation to the President's Drug Pricing Blueprint, the NPF advocated for patient priorities as they relate to potential Congressional proposals to move Medicare Part B drugs into Part D, adjust out of pocket expenses in Medicare Part D, and increase access to therapies. There was a particular focus on Congress's role in new policies around allowing step therapy protocols in Medicare Advantage plans.

Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

FY19 Appropriations for Psoriatic Disease Allocate $1 million in the Fiscal Year 2019 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.

In relation to the President's Drug Pricing Blueprint, the NPF advocated for patient priorities as they relate to potential Congressional proposals to move Medicare Part B drugs into Part D, adjust out of pocket expenses in Medicare Part D, and increase access to therapies. There was a particular focus on Congress's role in new policies around allowing step therapy protocols in Medicare Advantage plans.

Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

In relation to the President's Drug Pricing Blueprint, the NPF advocated for patient priorities as they relate to potential Congressional proposals to move Medicare Part B drugs into Part D, adjust out of pocket expenses in Medicare Part D, and increase access to therapies.

FY19 Appropriations for Psoriatic Disease Allocate $1 million in the Fiscal Year 2019 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.

Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act (HR 2999). This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

FY18 Appropriations for Psoriatic Disease Allocate $1.5 million in the Fiscal Year 2018 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Support the development of public health self-management interventions that would help persons with psoriasis and psoriatic arthritis better manage their health, including their mental health. This project would include collecting and analyzing data to determine what patients must do to achieve optimal health outcomes and would develop new or update existing self-management tools to support these persons. - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.

Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act. This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called speciality tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act. This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called speciality tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

FY18 Appropriations for Psoriatic Disease Allocate $1.5 million in the Fiscal Year 2018 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Support the development of public health self-management interventions that would help persons with psoriasis and psoriatic arthritis better manage their health, including their mental health. This project would include collecting and analyzing data to determine what patients must do to achieve optimal health outcomes and would develop new or update existing self-management tools to support these persons. - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.

FY18 Appropriations for Psoriatic Disease Allocate $1.5 million in the Fiscal Year 2018 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). Within this funding, the CDC would: - Support the development of public health self-management interventions that would help persons with psoriasis and psoriatic arthritis better manage their health, including their mental health. This project would include collecting and analyzing data to determine what patients must do to achieve optimal health outcomes and would develop new or update existing self-management tools to support these persons. - Better understand linkages between psoriasis and psoriatic arthritis and other multiple chronic conditions, to develop a focused public health applied research agenda for psoriatic disease.

Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Patients' Access to Treatments Act. This bill limits copayments, coinsurance and other cost-sharing and out of pocket expenses for so-called speciality tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. Urge Congress to support efforts that increase access to care for individuals living with psoriasis and psoriatic arthritis by supporting the Restoring the Patient's Voice Act (HR 2077). The bill reforms step therapy insurance protocols to ensure patients and providers have access to a clear exemption process. It establishes a patient and provider friendly step therapy guidelines in ERISA regulated health insurance plans.

HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;

HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;

HR 2077 - Restoring the Patient's Voice Act; HR 2999 Patients' Access to Treatment Act; S 1113 - Personal Care Products Safety Act; Patient Access Issues; NIH/Health Research Funding;